Results 1 to 10 of about 485,344 (395)

Adjuvant therapeutic efficacy of low-dose aspirin on short-term outcomes of patients with cancer-associated venous thromboembolism [PDF]

BMC Medicine
Background Although aspirin was reported to have primary thromboprophylactic efficacy on cancer patients, its adjuvant role in the treatment of patients with cancer-associated venous thromboembolism (VTE) has been unclear yet.
Wei Xiong, Zhenzhong Deng, Yi Cheng, Xiaoyang Song, Qihuan Yao, Jianmin Qu, Mei Xu, Fengfeng Han, Xuejun Guo, Yong Luo   +9 more
doaj   +2 more sources

Paractamol or Aspirin? [PDF]

BMJ, 1965
G. H. Jennings
openalex   +4 more sources

The prevalence and associated factors of aspirin resistance among prophylactic aspirin users [PDF]

Romanian Journal of Neurology, 2021
Background. Aspirin is an antiplatelet used for the secondary prevention after vascular events. It is also suggested for the primary prevention of vascular events in high risk people, however, despite using standard prophylactic doses, aspirin resistance
Samaneh Ghorbani-Shirkouhi, Fatemeh Ashouri, Saeideh Aghayari Sheikh Neshin, Alia Saberi, Bahador Hasanzadeh, Parisa Shahshahani   +5 more
doaj   +1 more source

Pharmacological Efficacy and Gastrointestinal Safety of Different Aspirin Formulations for Cardiovascular Prevention: A Narrative Review

Journal of Cardiovascular Development and Disease, 2023
Aspirin inhibits platelet function by irreversibly inhibiting the synthesis of thromboxane A2 (TxA2). Aspirin, at low doses, is widely used for cardiovascular prevention. Gastrointestinal discomfort, mucosal erosions/ulcerations and bleeding are frequent
Bianca Clerici, Marco Cattaneo
doaj   +1 more source

P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis

Journal of the Formosan Medical Association, 2022
Background/Purpose: Antiplatelet therapy is the cornerstone for acute ischemic stroke or transient ischemic attack (TIA). The purpose of this study was to conduct a meta-analysis to assess the efficacy and safety of P2Y12 receptor inhibitor plus aspirin ...
Wen-Yi Huang, Bruce Ovbiagele, Meng Lee
doaj   +1 more source

Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.

Journal of the American Medical Association (JAMA), 2022
Importance Cardiovascular disease (CVD) is the leading cause of mortality in the US, accounting for more than 1 in 4 deaths. Each year, an estimated 605 000 people in the US have a first myocardial infarction and an estimated 610 000 experience a first ...
K. Davidson, M. Barry, C. Mangione, Michael Cabana, D. Chelmow, Tumaini R. Coker, E. Davis, Katrina E. Donahue, C. Jaén, A. Krist, Martha Y. Kubik, Li Li, G. Ogedegbe, L. Pbert, J. Ruiz, J. Stevermer, Chien-Wen Tseng, J. Wong   +17 more
semanticscholar   +1 more source

Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy

Frontiers in Oncology, 2022
Gonadotropin-releasing hormone (GnRH) therapy has been known to increase risks of major adverse cardiovascular and cerebrovascular events (MACCEs). Herein, we aim to estimate whether regular use of aspirin attenuates risks of MACCEs in prostate cancer ...
Wei-Ting Chang, Wei-Ting Chang, Wei-Ting Chang, Chon-Seng Hong, Chon-Seng Hong, Kun-Lin Hsieh, Kun-Lin Hsieh, Yi-Chen Chen, Chung−Han Ho, Chung−Han Ho, Jhih-Yuan Shih, Jhih-Yuan Shih, Wei-Chih Kan, Wei-Chih Kan, Zhih-Cherng Chen, You-Cheng Lin   +15 more
doaj   +1 more source

Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.

Journal of the American Medical Association (JAMA), 2022
Importance There remains a lack of randomized trials investigating aspirin monotherapy for symptomatic venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA) or total knee arthroplasty (TKA).
V. Sidhu, T-l Kelly, N. Pratt, S. Graves, R. Buchbinder, S. Adie, K. Cashman, Ilana Ackerman, Durga Bastiras, R. Brighton, A. Burns, B. Chong, O. Clavisi, Maggie Cripps, Mark Dekkers, R. de Steiger, Michael C. Dixon, Andrew Ellis, E. Griffith, D. Hale, Amber Hansen, A. Harris, R. Hau, M. Horsley, Dugal James, Omar Khorshid, L. Kuo, P. Lewis, David Lieu, M. Lorimer, S. MacDessi, P. Mccombe, C. McDougall, J. Mulford, J. Naylor, R. Page, J. Radovanović, M. Solomon, R. Sorial, P. Summersell, P. Tran, W. Walter, S. Webb, Christopher J Wilson, D. Wysocki, I. Harris   +45 more
semanticscholar   +1 more source

Blood loss after coronary artery bypass by aspirin responsiveness assessed with preoperative VerifyNow aspirin testing

Research and Practice in Thrombosis and Haemostasis, 2021
Background Aspirin is important for preventing thrombotic events but also increases bleeding complications. Minimizing bleeding while preventing thrombotic events remains challenging in patients undergoing coronary artery bypass grafting (CABG ...
Laura M. Willemsen, Eline A. Vlot, Paul W. A. Janssen, Claire D. Visser, Kai Zheng, Johannes C. Kelder, Peter G. Noordzij, Erik‐Jan van den Dool, Patrick Klein, Christian M. Hackeng, Jurrien M. ten Berg   +10 more
doaj   +1 more source

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects

Pharmaceutics, 2023
Acid-reducing agents are commonly used for the prevention of aspirin-induced gastrointestinal complications such as peptic ulcers. As a novel potassium-competitive acid blocker, fexuprazan is expected to prevent aspirin-induced gastrointestinal ...
JungJin Oh, Eunsol Yang, In-Jin Jang, Hyejung Lee, Hokyun Yoo, Jae-Yong Chung, SeungHwan Lee, Jaeseong Oh   +7 more
doaj   +1 more source